Health

STAT+: Merck suffers a setback in Europe over its new Keytruda formulation

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 07/10/2026, 21:21:26 UTC.

Briefings

A Dutch court ruled that Merck infringed on a patent for a subcutaneous Keytruda formulation, ordering a halt to manufacturing and marketing in France, Italy, Sweden, Switzerland, and the Netherlands. The ruling occurred during a broader patent dispute with Halozyme Therapeutics. Patients using the intravenous version remain unaffected by this specific court order. Merck strongly disagreed with the decision. The article was published on October 7, 2026, and the full story is available via a link.

Key points

• A Dutch court ordered Merck to halt manufacturing and marketing of a subcutaneous Keytruda formulation in France, Italy, Sweden, Switzerland, and the Netherlands due to patent infringement.
• The intravenous version of Keytruda remains available to patients and is not affected by the court ruling or the subsequent patent dispute with Halozyme Therapeutics.

Context and limitations

The article was published on October 7, 2026, and the full story is available via a link. The specific details of the patent dispute timeline and the exact scope of the subcutaneous formulation's patent are not fully detailed in the provided text.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/10/2026, 09:58:32 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeicsab5p3unst6qwsorlhczb2jc4qromm4gn2ipxniqjjqxk6htzgm